Freesy Tablet

About Freesy 20 mg Tablet

Freesy 20 mg Tablet is a prescription medicine from Square Pharmaceuticals PLC. It contains zafirlukast and is used for the ongoing prevention and long-term control of asthma in adults and older children. It is not a rescue medicine for sudden asthma attacks.

There are 4 brands of Zafirlukast listed in Bangladesh. The lowest listed price is Zafir 20 mg Tablet at ৳ 20.07 per unit.

What is Freesy 20 mg Tablet?

Freesy 20 mg Tablet is a leukotriene receptor antagonist, a type of medicine that blocks substances in the body involved in airway swelling and tightening during asthma. Doctors prescribe it for the prevention and chronic treatment of asthma in adults and children aged five years and older. It is taken regularly over time, including when there are no symptoms, and treatment is usually continued during flare-ups. It does not replace steroid treatment and is not meant to relieve a sudden attack. The doctor decides the dose and course for each person.

Uses of Freesy

Freesy 20 mg Tablet is used for the prevention and long-term treatment of asthma in adults and children aged five and older. Taken regularly, it is part of an ongoing asthma care plan. It is not used to reverse sudden breathing difficulty during an asthma attack, and it does not allow a reduction in existing steroid treatment. Anyone with asthma should follow the plan set by their doctor for daily control and for flare-ups.

How to use Freesy

Take Freesy 20 mg Tablet exactly as your doctor prescribes. The doctor decides the dose and how long you take it. Swallow the tablet as instructed; food may affect how the body absorbs zafirlukast, so ask your doctor or pharmacist about timing with meals. Take it regularly, even when you feel well, because it works as ongoing prevention. Do not stop or change the dose on your own, and do not use it for a sudden asthma attack.

Side effects of Freesy

In clinical trials, headache and stomach or bowel upset such as nausea, vomiting, diarrhoea and abdominal pain were reported. These are usually mild and often do not require stopping treatment. Bruising, bleeding problems, and some blood cell changes have been reported after the medicine became widely available. Tell your doctor if you notice unusual bruising, bleeding, or any troublesome symptom. Ask your doctor or pharmacist about anything you experience while taking this medicine.

Safety and precautions

Do not take Freesy 20 mg Tablet if you have had an allergic reaction to it or its ingredients, or if you have moderate or severe kidney problems, liver problems or cirrhosis. It is not for children under seven years. The safety of zafirlukast in human pregnancy has not been established, and it passes into breast milk, so it should not be given to nursing mothers; use in pregnancy only if clearly needed. Tell your doctor about pregnancy, breastfeeding, other medicines such as warfarin, and any health conditions before starting.

Frequently asked questions

What is Freesy 20 mg Tablet and what is it used for?

It is a prescription tablet containing zafirlukast, a leukotriene receptor antagonist. Doctors use it for the prevention and chronic treatment of asthma in adults and children aged five years and older. It is taken regularly and is not a rescue medicine for sudden attacks.

How should Freesy 20 mg Tablet be stored?

Keep it between 20-25° C, protected from light and moisture. Store it in its original packaging, away from children, and do not use it after the expiry date. Ask your pharmacist if you are unsure how to dispose of unused tablets.

Who should avoid Freesy 20 mg Tablet or ask a doctor first?

People with a history of allergy to it, moderate or severe kidney impairment, liver impairment or cirrhosis, and children under seven should not take it. Nursing mothers should not use it. Tell your doctor about pregnancy, breastfeeding, warfarin or other medicines, and any health conditions before starting.

Can Freesy 20 mg Tablet be used during an asthma attack?

No. It is not meant to reverse bronchospasm in an acute asthma attack and does not replace steroid treatment. Keep following your doctor's plan for sudden attacks. The doctor decides the dose and course of Freesy 20 mg Tablet and whether treatment continues during flare-ups.

Also available as

10 mg (Tablet)

Indications

Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

Pharmacology

Zafirlukast is a selective and competitive leukotriene-receptor antagonist (LTRA) of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway oedema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Dosage & Administration

Zafirlukast should be taken continuously.

Children under 7 years of age: There is no clinical experience of the use of Zafirlukast in children under 7 years of age until safety information is available.

Children over 7 years through 11 years of age: The recommended dose of Zafirlukast in this age group is 10 mg twice daily.

Adult and children aged 12 years and over: The dosage is one 20 mg tablet twice daily. This dosage should not be exceeded. Higher doses may be associated with elevations of one or more liver enzymes consistent with hepatotoxicity. As food may reduce the bioavailability of Zafirlukast, Zafirlukast should not be taken with meals

Elderly: The clearance of Zafirlukast is significantly reduced in elderly patients (over 65 years old), and Cmax and AUC are approximately double than those of younger adults. However, accumulation of Zafirlukast is not greater than that seen in multiple dose trials conducted in adult subjects with asthma and the consequences of the altered kinetic in the elderly are unknown. Clinical experience with Zafirlukast in the elderly (over 65 years) is limited and caution is recommended until further information is available.

Renal impairment: No dosage adjustment is necessary in patients with mild renal impairment.

Interaction

Zafirlukast may be administered with other therapies routinely used in the management of asthma and allergy. Inhaled steroids, inhaled and oral bronchodilator therapy, antibiotics and antihistamines are examples of agents which have been co-administered with Zafirlukast without adverse interaction.

Zafirlukast may be administered with oral contraceptives without adverse interaction. Co-administration with Warfarin results in an increase in maximum prothrombin time by approximately 35%. It is therefore recommended that if Zafirlukast is co-administered with Warfarin, prothrombin time should be closely monitored. The interaction is probably due to an inhibition by Zafirlukast of the cytochrome P450 2C9 enzyme system. In clinical trials co-administration with Theophylline resulted in decreased plasma levels of Zafirlukast, by approximately 30%, but with no effect on plasma Theophylline levels. However, during postmarketing surveillance, there have been rare cases of patients experiencing increased Theophylline levels when co-administered with Zafirlukast.

Co-administration with Terfenadine resulted in a 54% decrease in AUC for Zafirlukast, but with no effect on plasma Terfenadine levels. Coadministration with Acetylsalicylic acid (650 mg four times a day) may result in increased plasma levels of Zafirlukast, by approximately 45%.

Co-administration with Erythromycin will result in decreased plasma levels of Zafirlukast, by approximately 40%. The clearance of Zafirlukast in smokers may be increased by approximately 20%

Contraindications

Zafirlukast should not be given to patients who have previously experienced hypersensitivity to the product or any of its ingredients. Zafirlukast is contraindicated in patients with a history of moderate or severe renal impairment. Zafirlukast is contraindicated in patients with hepatic impairment or cirrhosis; it has not been studied in patients with hepatitis or in long term studies of patients with cirrhosis. Zafirlukast is contraindicated in children under 7 years of age until safety information is available.

Side Effects

Effect on ability to drive or operate machinery: There is no evidence that Zafirlukast affects the ability to drive and use machinery. Administration of Zafirlukast in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). These symptoms are usually mild and do not necessitate withdrawal from therapy. During post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.

Hypersensitivity reactions, including urticaria and angio-oedema have been reported. Rashes, including blistering, have also been reported. The above events have usually resolved during continued treatment or following cessation of therapy.

Infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with Zafirlukast (increased AST 1.0% vs. 0.9%, increased AST 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. Rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of Zafirlukast therapy. During post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. These cases were usually reversible.

In placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given Zafirlukast (7.8% vs. 1.4%). Infections were usually mild, predominantly affecting the respiratory tract.

Pregnancy & Lactation

Pregnancy: The safety of Zafirlukast in human pregnancy has not been established. In animal studies, Zafirlukast did not have any apparent effect on fertility and did not appear to have any teratogenic or selective toxic effect on the foetus. The potential risks should be weighed against the benefits of continuing therapy during pregnancy and Zafirlukast should be used during pregnancy only if clearly needed.

Lactation
: Zafirlukast is excreted in human breast milk. Zafirlukast should not be administered to nursing mothers.

Precautions & Warnings

Zafirlukast should be taken regularly to achieve benefit, even during symptom free periods. Zafirlukast therapy should normally be continued during acute exacerbations of asthma. Zafirlukast does not allow a reduction in existing steroid treatment. As with inhaled steroids and hormones (disodium cromoglycate, nedocromil sodium), Zafirlukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Zafirlukast has not been evaluated in the treatment of labile (brittle) or unstable asthma.

Cases of Churg Strauss syndrome have been reported in association with Zafirlukast usage. A causal relationship has neither been confirmed nor refuted. If a patient develops a Churg Strauss syndrome type illness, Zafirlukast should be stopped, a re-challenge test should not be performed and treatment should not be restarted.

Elevations in serum transaminases can occur during treatment with Zafirlukast. These are usually asymptomatic and transient but could represent early evidence of hepatotoxicity.

If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, right upper quadrant pain, fatigue, lethargy, flu-like symptoms, enlarged liver, pruritus and jaundice), the serum transaminases, in particular serum ALT, should be measured and the patient managed accordingly. A decision to discontinue Zafirlukast should be individualized to the patient’s condition, weighing the risk of hepatic dysfunction against the clinical benefit of Zafirlukast to the patient.

Storage Conditions

Store between 20-25° C. Protect from light and moisture.

Alternative brands of Zafirlukast

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.